Oral anticoagulation with rivaroxaban during pregnancy: a case report

Oliver Königsbrügge; Martin Langer; Michael Hayde; Cihan Ay; Ingrid Pabinger

doi:10.1160/th14-04-0393

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2014; 112(06): 1323-1324
DOI: 10.1160/th14-04-0393

Letters to the Editor

Schattauer GmbH

Oral anticoagulation with rivaroxaban during pregnancy: a case report

Oliver Königsbrügge

¹Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Austria

,

Martin Langer

²Department of Obstetrics and Gynaecology, Medical University of Vienna, Austria

,

Michael Hayde

³Clinical Division of Paediatric Neonatology, Intensive Care and Neuropaediatrics, Medical University of Vienna, Austria

,

Cihan Ay

¹Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Austria

,

Ingrid Pabinger

¹Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Austria

References
1 Fenton T, Kim J. A systematic review and metaanalysis to revise the Fenton growth chart for preterm infants. BMC Pediatr 2013; 13: 59.
2 Bates SM, Greer I, Middeldorp S. et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e691S-736S.
3 European Medicines Agency. CHMP Assessment report for Xarelto. Doc.Ref.: EMEA/543519/2008. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000944WC500057122.pdf Accessed April 2, 2014.
4 European Medicines Agency. Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf Summary of product characteristics. Accessed April 3, 2014.
5 Freude S, Pabinger-Fasching I, Kozel-Lachmann D. et al. Warfarin embryopathy in maternal coumarin therapy for protein S deficiency. Padiatr Padol 1991; 26: 239-241.
6 Mehndiratta S, Suneja A, Gupta B. et al. Fetotoxicity of warfarin anticoagulation. Arch Gynecol Obstet 2010; 282: 335-337.
7 Masamoto H, Uehara H, Mekaru K. et al. Warfarin- associated fetal intracranial hemorrhage in woman with mitral valve replacements: a case report. Am J Perinatol 2009; 01: 597-600.
8 Chan W, Anand S, Ginsberg J. Anticoagulation of pregnant women with mechanical heart valves. Arch Intern Med 2000; 160: 191-196.
9 Iturbe-Alessio I, Fonseca M, Mutchinik O. et al. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 1986; 315: 1390-1393.
10 Hassouna A, Allam H. Limited dose warfarin throughout pregnancy in patients with mechanical heart valve prosthesis: a meta-analysis. Interact Cardiovasc Thorac Surg 2014; 18: 797-806.
11 Bain E, Wilson A, Tooher R. et al. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev. 2014 Epub ahead of print.
12 Romualdi E, Dentali F, Rancan E. et al. Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature. J Thromb Haemost 2013; 11: 270-281.